| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 21043 |
| Drug | Nivolumab |
| Brand | Opdivo® |
| Indication | Nivolumab as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. |
| Assessment Process | |
| Rapid review commissioned | 21/09/2021 |
| Rapid review completed | 20/10/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 28/10/2021 |
| Pre-submission consultation with Applicant | 20/12/2021 |
| Full submission received from Applicant | 11/05/2022 |
| Preliminary review sent to Applicant | 24/10/2022 |
| NCPE assessment re-commenced | 21/11/2022 |
| Factual accuracy sent to Applicant | 23/01/2023 |
| NCPE assessment re-commenced | 30/01/2023 |
| NCPE assessment completed | 13/02/2023 |
| NCPE assessment outcome | The NCPE recommends that nivolumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
